Add Coronavirus Press Release Electronically Sign with airSlate SignNow

Add initials Coronavirus Press Release

good morning we would like to welcome all of you to our virtual press conference today to discuss the fda's authorization of the updated booster doses of the moderna and pfizer bioentech clobid19 vaccines first we will hear from fda commissioner dr robert m califf and then from dr peter marks the director of the fda center for biologics evaluation and research following their remarks we will allow time for questions from the media with that let's turn over the press conference to dr caleb thanks to everyone for joining as we all know unfortunately copenhagen continues to cause devastating consequences throughout the country with nearly 400 deaths and over 5 000 new hospitalizations every day and just yesterday provisional cdc data indicated that u.s life expectancy fell again in 2021 in large part due to covet deaths although the current cobia 918 surge is waning overall it's predicated that we'll enter yet another surge as we spend more time indoors later this fall and winter we also know that staying up to date on vaccines is the best way to protect yourself from coca-19 and its most devastating consequences and as the virus has evolved the original vaccine is not as protective against the currently circulating strains as it was against the original virus with that in mind we have been planning for and gathering input on our approach to updated boosters since earlier this year the fda has extensive experience with evaluating strain changes for influenza vaccines and is confident in the data supporting these latest booster authorizations and importantly the approach we're taking with the updated coca-19 booster vaccines mirrors how we have historically addressed changes for the influenza vaccine today the fda authorized updated boosters of both the moderna and pfizer bioin tech copit19 vaccines these formulations of the vaccines are authorized for use as a single booster dose at least two months following primary or booster vaccination these updated boosters are known as bivalent vaccines because they contain two messenger rna components of sars kovi-2 virus one from the original strain of thesaurus kobe 2 and the other one in common between the va.4 and ba.5 omicron variant lineages of sars kobe 2. the authorization for the updated moderna covet 19 vaccine booster applies to individuals 18 years of age and older and the authorization for the updated pfizer bioin tech covid19 vaccine booster applies to individuals 12 years of age and older individuals in these age groups are eligible for the respected boosters if it's been at least two months since they've completed primary vaccination or have received the most recent booster dose with any authorized or approved monovalent copin 19 vaccine the updated boosters contain the same basic ingredients as the original cobin 19 mrna vaccines but are modified to target the circulating omicron variant ba4 and ba5 as well as the strain that was included in the original vaccines these updated boosters meet the fda's rigorous standards and are expected to help...